Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab.
Joo Young HaJeong Eun KimHee Jin LeeJae Ho JungJin-Hee AhnKyung Hae JungGyungyub GongEun Young ChaeHak Hee KimIl-Young ChungBeom Seok KoSung-Bae KimPublished in: Journal of breast cancer (2021)
HR status and the TILs grade are significantly correlated with pCR in dual anti-HER2 neoadjuvant therapy. The evaluation of the TILs at baseline may be beneficial for predicting pCR in HER2-positive breast cancer.
Keyphrases
- positive breast cancer
- epidermal growth factor receptor
- locally advanced
- rectal cancer
- phase ii study
- tyrosine kinase
- advanced non small cell lung cancer
- lymph node
- endothelial cells
- squamous cell carcinoma
- radiation therapy
- real time pcr
- induced pluripotent stem cells
- peripheral blood
- randomized controlled trial
- clinical trial
- stem cells
- bone marrow
- mesenchymal stem cells
- open label
- smoking cessation
- study protocol